Sanofi’s latest Dupixent win and Eupraxia Pharmaceuticals’ quiet grind in eosinophilic esophagitis (“EoE”) still tell a coherent, investor‑friendly story: the type 2 inflammation boom is alive, and there is room on the highway for both mega‑cap platforms and focused innovators. For investors, the pairing of Sanofi (NASDAQ: SNY) and Eupraxia (TSX: EPRX, NASDAQ: EPRX) offers a classic barbell—defensive cash flows on one side, high‑beta optionality on the other.
A New Bull Market in Blisters
In June 2025, Sanofi and Regeneron (NASDAQ: REGN) secured US FDA approval for Dupixent as the first targeted medicine for bullous pemphigoid, an intensely itchy, blistering autoimmune skin disease that disproportionately affects older adults. The label rests on ADEPT, a phase 2/3 study in which Dupixent delivered sustained disease remission, clinically meaningful itch reduction, and lower cumulative oral steroid exposure versus placebo in a population long dependent on steroids with significant toxicity. Bullous pemphigoid may look niche on paper, but it is another brick in a very large wall: Dupixent is now approved in the US across eight distinct type 2 inflammatory diseases spanning dermatology, pulmonology, and gastroenterology, with more than one million patients treated globally. For markets trying to identify genuine “platform” biologics, this is what a functioning platform looks like—one mechanism, multiple indications, and a payor narrative that deepens with every label expansion.
Type 2 Inflammation Goes Mainstream
Mechanistically, Dupixent is a fully human monoclonal antibody targeting interleukin‑4 and interleukin‑13 signaling, central cytokines in type 2 inflammation that drive diseases such as atopic dermatitis, asthma, EoE, chronic rhinosinusitis with nasal polyposis, and now bullous pemphigoid. Sanofi and Regeneron have deliberately positioned Dupixent as a “type 2 axis” drug rather than a single‑disease product, creating a framework for systematic expansion into new indications where the same biology underpins very different symptoms. Regulators are playing along: for bullous pemphigoid, Dupixent received orphan designation and priority review, underscoring FDA’s willingness to reward first‑in‑class solutions even in relatively small populations. With additional regulatory submissions in regions including the EU, Japan, and China either filed or planned, the geographic and label expansion arc for Dupixent remains very much in motion.
The Orphan Innovation Playbook
Sanofi estimates that approximately 27,000 adults in the US have bullous pemphigoid that is inadequately controlled with systemic steroids, a cohort where both disease burden and treatment side effects are substantial. In ADEPT, Dupixent increased the proportion of patients achieving sustained remission, reduced itch to levels that materially improved daily functioning, and enabled lower steroid exposure, a combination that resonates strongly with clinicians managing frail, comorbidity‑heavy patients. Importantly, the safety profile in bullous pemphigoid remained consistent with Dupixent’s broader experience, with common adverse events including arthralgia, conjunctivitis and other eye disorders, and herpes viral infections, but no new safety signals emerging. For a chronic therapy aimed at older patients, that continuity of safety across indications is a key part of the commercial story, because it reduces friction when specialists consider adding one more disease to the Dupixent universe.
From French Giant to Canadian Upstart
On the other side of the market‑cap spectrum, Eupraxia Pharmaceuticals is crafting a very different, but complementary, story with its proprietary Diffusphere technology. The company’s thesis is to use extended‑release, locally targeted delivery to transform familiar pharmacology into differentiated, organ‑specific therapies, thereby maximizing efficacy at the site of disease while minimizing systemic exposure. EP‑104GI, Eupraxia’s lead EoE program, leverages this platform to deliver a corticosteroid directly into the esophageal wall via a series of injections, designed to release drug slowly over extended periods. In parallel, EP‑104IAR applies the same technological logic to knee osteoarthritis in the SPRINGBOARD program, giving Eupraxia a pipeline that spans gastroenterology and musculoskeletal indications from a common delivery backbone.
RESOLVE: A New Script for EoE
EoE is a chronic, immune‑mediated condition where eosinophils (a type of white blood cell) infiltrate the esophageal lining, causing inflammation, tissue damage, and scarring. Clinically, it presents with symptoms such as difficulty swallowing, food impactions, chest pain, and in children, feeding difficulties and poor growth. The disease is closely linked to allergic tendencies, with many patients also having asthma, allergic rhinitis, or eczema and showing sensitivity to specific foods or environmental allergens. Over time, untreated EoE can lead to esophageal narrowing and strictures, increasing the risk of acute food impactions and the need for endoscopic interventions. Eosinophilic Esophagitis (EoE) is no longer considered a rare disease in the USA, with an estimated prevalence of 1 in 700 people. This translates to approximately 472,380 active cases nationwide, with a rapidly growing year-over-year diagnosis rate. Due to the rise in diagnoses and the need for ongoing treatments, EoE places a substantial economic burden on the US healthcare system. Total EoE-associated annual costs are estimated at over $1.3 billion.
The RESOLVE Phase 1b/2a trial in EoE is rapidly becoming the proof‑of‑concept engine behind Eupraxia’s valuation. Low‑dose cohorts demonstrated tolerability and early signs of efficacy, with reductions in patient‑reported symptom scores (such as the Straumann Dysphagia Index) and histologic improvements in EoEHSS and peak eosinophil counts at 12 weeks, encouraging the company to escalate dose and expand the trial. By January 2026, Eupraxia was reporting its most striking data to date: in Cohort 9, the highest‑dose group (8 mg per site across 20 sites), patients achieved approximately 94 percent and 97 percent improvements in EoEHSS grade and stage respectively at week 12, approaching near‑complete normalization of tissue health on biopsy. At intermediate dose levels (4 mg per site across 12–20 sites), patients maintained tissue health gains from week 12 out to week 36, while clinical remission was achieved in a majority of patients by week 8 and sustained through week 52 in those who had at least 60 percent of their esophagus treated.
Symptom Relief That Sticks
Symptoms drive both quality‑of‑life and prescribing behavior, and here EP‑104GI is delivering the kind of durable response profile that catches specialists’ attention. Across RESOLVE, higher dose and more extensive injection protocols produced larger reductions in dysphagia and other EoE symptoms, with many patients entering and maintaining clinical remission based on standardized symptom scales at 12, 24, and 52 weeks. Endoscopic outcomes align with the histology and symptoms: EREFS scores improved substantially, and in higher‑dose cohorts many patients approached near‑complete endoscopic normalization by week 12, with durability extending out to 9–12 months. Importantly, the safety profile remained clean, with no drug‑related serious adverse events and no cases of oral or gastrointestinal candidiasis reported across hundreds of patient‑months, a key differentiator in a disease where chronic steroid exposure often raises candidiasis concerns.
Toward a Potential Once‑a‑Year Paradigm
Beyond the headline numbers, the cadence of effect may be the most intriguing aspect of EP‑104GI. Data from early and mid‑dose cohorts show that symptom and tissue improvements can persist for at least six months after a single intra‑esophageal injection series, and modeling from the RESOLVE program suggests that dosing intervals of 6–12 months may be feasible at higher doses. Eupraxia has highlighted 12‑month data from select cohorts in which two‑thirds of patients at certain dose levels remained in clinical remission a year after treatment, supporting the concept of aligning EP‑104GI dosing with routine annual endoscopies. If that profile holds in later‑stage trials, EP‑104GI could define a new treatment paradigm in which many EoE patients transition from daily steroids or weekly biologic injections to a “once‑a‑year” procedural reset.
Funding the Long March to Q3 2026 and Beyond
From a capital‑markets perspective, Eupraxia’s story is increasingly about execution rather than survival. For the first quarter of 2026, the company reported a net loss of approximately 12.7 million dollars, reflecting increased R&D spend as RESOLVE and other programs advanced, offset by a strengthened balance sheet that includes roughly 58.5 million dollars in cash and cash equivalents and more than 80 million dollars in short‑term investments. A recently completed public offering raised approximately 63.2 million dollars, extending the company’s funding runway into the second half of 2028 and reducing near‑term financing overhang. With about 61.8 million common shares and 8.4 million preferred shares outstanding as of March 31, 2026, EPRX remains a classic clinical‑stage equity story—dilutive, but now backed by robust proof‑of‑concept data and a clear line of sight to the next major catalyst.
Key Upcoming EoE Milestones
For investors tracking catalysts, Eupraxia has already mapped out several important waypoints in EoE. The Phase 2b portion of RESOLVE—a randomized, placebo‑controlled study of EP‑104GI at a 120 mg total dose (20 injections of 6 mg)—is currently recruiting, with top‑line data expected in the third quarter of 2026, representing the next major inflection point for the program. Regulators in Australia and Canada have approved expansions to the RESOLVE protocol to explore higher doses, more injection sites, and longer follow‑up, with participant counts increasing and follow‑up durations extended to 52 weeks at higher doses, further enriching the dataset ahead of a potential registration trial. Taken together, these steps set up a 2026–2027 window in which EP‑104GI could transition from early‑stage curiosity to a late‑stage, registration‑ready asset if the Phase 2b outcomes align with current trends.
When Big‑Cap Proof Meets Small‑Cap Optionality
Sanofi’s Dupixent story and Eupraxia’s EP‑104GI arc intersect in their shared focus on type 2 inflammation and EoE, but diverge in scale and strategic flexibility. For large‑cap investors, Sanofi’s latest approval reinforces the view that Dupixent remains a multi‑indication growth engine, extending into rare dermatologic disease while maintaining a consistent safety and efficacy profile across age groups and organ systems. For small‑cap and crossover investors, Eupraxia offers leveraged exposure to the same macro thesis from a different angle: a technology‑driven, extended‑release approach that may complement—or in some settings compete with—systemic biologics in EoE and beyond. In a world where big pharma often prefers to acquire derisked assets rather than build from scratch, that pairing of clean safety, durable efficacy, and multi‑year runway has obvious strategic appeal.
Could Eupraxia Become an Acquisition Target?
Eupraxia’s EoE program is not simply adding another topical steroid to the mix; it is aiming for a structurally different proposition: a durable, locally delivered therapy that may only need to be given once every 6–12 months while still delivering sustained histologic and symptomatic control. Early RESOLVE data suggest that high‑dose cohorts can maintain near‑normalized tissue health and high rates of clinical remission at 9–12 months post‑treatment, a profile that naturally invites comparison with chronic, often weekly or biweekly, biologic injections like Sanofi and Regeneron’s Dupixent. That contrast is likely to raise eyebrows at any company with a serious stake in immunology: an annual procedure‑based therapy could be viewed as a competitive threat in some patient segments, or as a portfolio complement that allows a single commercial platform to address both systemic and localized disease control. For payors, a product that potentially replaces dozens of injections or daily oral steroids with a single annual intervention could also stand out economically, especially if real‑world adherence with biologics remains imperfect. On the corporate development side, Eupraxia checks several boxes that acquirers tend to like: a clearly differentiated technology (Diffusphere), compelling early‑ and mid‑stage data in a defined high‑need indication, a pipeline that extends beyond a single asset, and a funding runway that reduces the risk of distressed selling. With EP‑104GI’s Phase 2b top‑line data expected in Q3 2026 and a potential registration‑trial start not far behind, the next 12–24 months could be the period in which larger immunology players decide whether they want EP‑104GI in their “threat matrix” or in their portfolio.
The Sources
- Sanofi – Dupixent bullous pemphigoid approval (June 20, 2025)
https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-20-05-00-00-3102518 - Sanofi – Dupixent EoE Phase 3 and pediatric data (press and media room)
https://www.news.sanofi.us/2024-01-25-Dupixent-R-FDA-approved-as-first-and-only-treatment-indicated-for-children-aged-1-year-and
https://www.sanofi.com/en/media-room/press-releases/2022/2022-10-11-05-00-00-2531406 - Dupixent EoE clinical trial design and efficacy (HCP site)
https://www.dupixenthcp.com/eoe/efficacy-safety/study-design - Sanofi – Dupixent EoE trial meets primary endpoints (adult/adolescent EoE press release)
https://www.sanofi.com/en/media-room/press-releases/2020/2020-05-22-22-25-00-2037859 - Regeneron – Dupixent improves esophageal function in EoE
https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-demonstrates-improved-esophageal-function - Dupixent® for EoE – patient‑facing information
https://www.dupixent.com/eoe/ - Sanofi stock information (SNY)
https://finance.yahoo.com/quote/SNY/
https://www.sanofi.com/en/investors/sanofi-share-and-adrs/stock-chart - Eupraxia Pharmaceuticals – corporate site and pipeline overview
https://eupraxiapharma.com
https://www.eupraxiapharmaceuticals.com/wp-content/uploads/2025/08/2024_09_10_ISDE-2024-EoE-poster_FINAL.pdf - Eupraxia – RESOLVE Phase 1b/2a EoE trial data (initial and updated)
“Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP‑104GI”
https://investors.eupraxiapharma.com/news-releases/news-release-details/eupraxia-pharmaceuticals-announces-sustained-positive-tr “RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near‑Complete Improvement on Biopsy”
https://investors.eupraxiapharma.com/news-releases/news-release-details/eupraxia-pharmaceuticals-reports-positive-tissue-health- - Eupraxia – Six‑month symptom data in EoE
“Eupraxia Pharmaceuticals Reports Six‑Month Symptom Data from RESOLVE Trial”
https://investors.eupraxiapharma.com/news-releases/news-release-details/eupraxia-pharmaceuticals-reports-six-month-symptom-data- - Eupraxia – Additional 52‑week RESOLVE data (EP‑104GI in EoE)
https://investors.eupraxiapharma.com/node/8176/pdf - Eupraxia – Diffusphere™ technology and EP‑104GI duration data
https://www.eosnetwork.org/news/diffusphere-advancing-targeted-drug-delivery
Pharmacokinetics/PK poster:
https://www.eupraxiapharmaceuticals.com/wp-content/uploads/2025/08/2024_ACG_NonClinical-Poster_FINAL_Eposter.pdf - Eupraxia – RESOLVE trial clinical‑trial listing (EP‑104GI in adults with EoE)
https://ctv.veeva.com/study/a-trial-evaluating-ep-104iar-in-adults-with-eosinophilic-esophagitis - Eupraxia – Press coverage of early RESOLVE cohorts
“EP‑104GI Performs Well in Eosinophilic Esophagitis (EoE)”
https://patientworthy.com/2024/06/11/ep104gi-performs-well-eosinophilic-esophagitis-eoe-trial/ - Eupraxia – New RESOLVE EREFS data (Digestive Disease Week)
https://www.stocktitan.net/sec-filings/EPRX/6-k-eupraxia-pharmaceuticals-inc-current-report-foreign-issuer-f91c1e13a03a.html - Eupraxia – 12‑month RESOLVE results update (conference presentation)
https://www.linkedin.com/posts/eupraxia-pharmaceuticals-inc-_eupraxia-eoe-biotech-activity-7369089114626777088-LCLQ - Eupraxia – Corporate and pipeline profile (Life Sciences BC)
https://lifesciencesbc.ca/member/eupraxiapharmaceuticals/ - Eupraxia – General company news and financials (Q1 2026 and beyond)
Q1 2026 financial results:
https://investors.eupraxiapharma.com/news-releases/news-release-details/eupraxia-pharmaceuticals-reports-first-quarter-2026-financial
Yahoo Finance press distribution of the same:
https://finance.yahoo.com/news/eupraxia-pharmaceuticals-reports-first-quarter-210000153.html - Sanofi – broader Dupixent EoE development program overview
https://www.sanofi.com/en/media-room/press-releases/2022/2022-10-11-05-00-00-2531406 (pediatric EoE Phase 3)
https://www.sanofi.com/en/media-room/press-releases (general Dupixent and immunology pipeline updates) - Scientific literature – Dupilumab in adult EoE
“Efficacy of Dupilumab in a Phase 2 Randomized Trial in Eosinophilic Esophagitis” (PubMed)
https://pubmed.ncbi.nlm.nih.gov/31593702/
Stay Updated with Vista Partners
Subscribe to receive market insights, investing ideas, and the latest updates directly in your inbox.
